Examining immune cell responses to teclistamab in multiple myeloma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to analyze the immune and oncogenomic characteristics that differentiate patients with multiple myeloma who respond to teclistamab from those who exhibit resistance. By focusing on single immune cell examination, the research will investigate both phenotypic and genotypic traits associated with primary and secondary resistance to the treatment. Bone marrow samples will be collected from participants to facilitate this analysis. The findings could provide insights into personalized treatment strategies for multiple myeloma.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* With multiple myeloma
* Who receive Teclistamab
* Consent form signed

Exclusion Criteria:

* Patient under legal protection

Where it's running

• CHU d'Amiens
  Amiens, France, France Recruiting
• CHU de Caen
  Caen, France, France Recruiting
• Polyclinique du Parc Drevon
  Dijon, France, France Recruiting
• CH Annecy Genevois
  Epagny Metz- Tessy, France, France Recruiting
• CHU de Lille
  Lille, France, France Recruiting
• Centre Léon Bérard
  Lyon, France, France Recruiting

Study contacts

• Principal investigator: Hervé AVET LOISEAU, MD, PhD — University Hospital, Toulouse
• Study coordinator: Hervé AVET LOISEAU, MD, PhD
• Email: avetloiseau.herve@iuct-oncopole.fr
• Phone: +33 531 156 142

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tec Dara for newly diagnosed multiple myeloma with light chain amyloidosis

  This study tests whether tec listamab plus daratumumab can help newly diagnosed multiple myeloma with AL amyloidosis and whether the combination is safe.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai · NCT07638683

• A comparison of JNJ-79635322 and teclistamab in relapsed or refractory multiple myeloma

  This study tests whether JNJ-79635322 works differently from teclistamab in people with relapsed or refractory multiple myeloma who have had prior therapy.

  Recruiting at 173 sites Phase 3 Janssen Research & Development, LLC · Birmingham, Alabama and 172 other locations · NCT07518186

• Teclistamab plus mezigdomide for relapsed or refractory multiple myeloma

  This trial will try a combination of teclistamab and mezigdomide in people with relapsed or refractory multiple myeloma who have had at least two prior therapies including a proteasome inhibitor, an IMiD, and an anti‑CD38 antibody.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07105059

• Daratumumab followed by teclistamab with RVd for newly diagnosed multiple myeloma

  This test tries whether switching from daratumumab plus RVd to teclistamab plus RVd after three treatment cycles is safe for people with newly diagnosed multiple myeloma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07099391

• T-cell therapies talquetamab and teclistamab to clear minimal residual disease after transplant in newly diagnosed myeloma (ROTATE)

  This tests whether giving talquetamab to patients who are MRD positive after induction and transplant, and switching to teclistamab if MRD doesn't clear, can make them MRD negative.

  Recruiting at 3 sites Phase 2 Yale University · New Haven, Connecticut and 2 other locations · NCT06993675

• Using bispecific T-cell redirectors for first-line treatment in transplant-eligible multiple myeloma patients

  This study is testing if a new combination of treatments can help newly diagnosed multiple myeloma patients who are eligible for a stem cell transplant feel better and improve their outcomes.

  Recruiting Phase 2 North Estonia Medical Centre · Copenhagen and 6 other locations · NCT06505369

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.